Image: Jessica Kourkounis / Stringer via Getty Images
2 min. read
Medicare, which now covers more than 67 million people, faces persistent financing pressures; rapid changes in care delivery; and growing debate over how best to pay for care, encourage innovation, and protect beneficiaries.
These are the kinds of problems that Amol Navathe will tackle as the new chair of the Medicare Payment Advisory Commission, or MedPAC, the independent congressional agency that advises lawmakers on Medicare payment policy, access to care, quality, and other issues affecting the program. Navathe, a professor of health policy and medicine at the Perelman School of Medicine, healthcare management at the Wharton School, and a senior fellow at Penn’s Leonard Davis Institute of Health Economics, takes on the role at a pivotal moment for Medicare, charged with helping figure out how to sustain the program financially while preserving access and quality for millions of older adults and people with disabilities.
As chair, Navathe explains, “my responsibility is to help keep the commission focused on its core mission: providing Congress with rigorous, independent analysis and advice aimed at improving the Medicare program and the health and welfare of its beneficiaries.”
Navathe outlines the challenges ahead. “Financial sustainability is top of mind for me, especially as new technologies such as AI-based devices and services continue to emerge. The challenge will be balancing access to promising innovations with financial prudence for beneficiaries and taxpayers, such as AI technologies that autonomously provide health care services like cognitive-behavioral therapy to people with depression.”
“At the same time,” he adds, “I see an opportunity for Medicare policy to continue evolving in ways that support better care delivery like improving access to behavioral health care, driving improved outcomes, and long-term program sustainability.”
Read more at Penn Medicine News.
From Penn Medicine News
Image: Jessica Kourkounis / Stringer via Getty Images
(Image: Lance Nelson)
Image: shih-wei via Getty Images
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
(Image: Kevin Monko/Penn Dental Medicine)